Induction of angiogenesis by normal and malignant plasma cells.
about
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialExtracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myelomaMithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factorsEx-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyThymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.Cyclin K and cyclin D1b are oncogenic in myeloma cells.Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivoProliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.Microvesicles secreted from human multiple myeloma cells promote angiogenesis.The glycome of normal and malignant plasma cellsInsulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesIntegrative analyses reveal novel strategies in HPV11,-16 and -45 early infection.Platelet factor 4 induces cell apoptosis by inhibition of STAT3 via up-regulation of SOCS3 expression in multiple myelomaIdentification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1Matricellular proteins as regulators of cancer metastasis to bone.The molecular characterization and clinical management of multiple myeloma in the post-genome era.Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors.The microenvironment in mature B-cell malignancies: a target for new treatment strategiesPeripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Biological aspects of angiogenesis in multiple myeloma.Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Targeting the bone marrow microenvironment in multiple myeloma.The role of CCN family genes in haematological malignancies.Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionIn vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionHOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.Angiogenesis and multiple myeloma.Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.Sorafenib in patients with refractory or recurrent multiple myeloma.
P2860
Q28075927-267CAF8D-C432-4011-8504-7725F0C94288Q28077635-C869F7CE-5354-443F-8E90-C4F106DFE285Q28487743-BA785714-7D6F-40E3-B632-AB337312896CQ28535634-4E268331-A45B-408A-B46F-EAF6B03DBDCDQ33587558-22A9043E-3ECF-48BA-9F2A-8CF4F5EB0FB2Q33748979-C3E41BB9-2C17-4B05-9927-457D8CB69F69Q33895292-C041BD20-A975-46A4-9723-E69679FB1D9AQ33938595-F82CDBBA-8521-481C-846A-A8293FE78C2FQ34451553-F37EAB04-C43E-46FF-B330-4DA52D141A70Q35077269-BC9E1498-C022-4E72-BE98-99794EBC5758Q35080602-3FE90F2C-9C12-4E73-BB31-A82CCCD2C3BDQ35097641-D18A9E1A-B674-4F4E-8AAE-4AA5F48B097CQ35244865-F5779449-A62A-4169-A9BC-6A698E8070AAQ36099378-D0B90958-C659-4808-89AE-06A2C7E8045CQ36579136-9D5C2F23-4C97-4E5A-939A-23A144BEF089Q36717999-B6A82ADB-07E6-48A5-B744-6A8DE456333BQ36923653-1270932C-8601-4683-BC93-86409B1E2D40Q36939043-BE4150D6-8DBC-4776-855B-A14A96D641B6Q37144899-563D44EC-5907-491D-A0B0-EC3DCE2BE542Q37373624-60E76965-9309-4CD8-A701-B8B0FE7826BEQ37563816-0099DAD3-7E3A-4A19-9C24-92FCF1AB3F54Q37760210-F2A2CEBB-387B-4451-B90D-4208C9F78DB5Q37761370-CFA74014-3259-4407-B8CF-CFAEBF6245D5Q37956524-C1670230-00DB-4CE4-A0ED-5FEB770A4D86Q38008379-C3B09974-B11C-477B-BFC8-DF3673ECC272Q38289041-985CC926-F157-4587-BFDF-88FCE8D100E0Q38508845-DF58823B-FDDB-431E-99F8-2B686D96C999Q38588911-369B6C9D-B691-44D9-958D-D166AE6CED31Q38673891-CB019FBC-3BBE-4B5B-84E3-27930CDCA2B4Q38910971-9F724DB9-D2CD-4538-BEC0-8EA60231260EQ39030703-9D0421F7-73B6-4F6E-BCE1-E1E04B8E1188Q39616165-E7BFD660-2095-4C9A-AC7C-EF86F136CDA4Q39696428-330DA8B6-561B-41D1-A04D-84A7AA8C4E46Q40274316-9CBB1535-17A4-46AB-8FCD-DAE5F9135A84Q40691084-902A50BF-D946-492D-AA0F-F2186CD10D9FQ42324181-9736CBEF-55D6-4B3C-B052-EB5EF4618E45Q43067059-A19130C5-8007-4E5E-B8E7-12152EBA942BQ43483788-68FDB781-F168-4912-BC13-0ECF4BB9F1A0Q43647817-83E64A9E-F636-441D-B17A-19C8379FF89AQ44579838-952BE959-1D07-4FD5-86E5-9F66F8387E2F
P2860
Induction of angiogenesis by normal and malignant plasma cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Induction of angiogenesis by normal and malignant plasma cells.
@en
Induction of angiogenesis by normal and malignant plasma cells.
@nl
type
label
Induction of angiogenesis by normal and malignant plasma cells.
@en
Induction of angiogenesis by normal and malignant plasma cells.
@nl
prefLabel
Induction of angiogenesis by normal and malignant plasma cells.
@en
Induction of angiogenesis by normal and malignant plasma cells.
@nl
P2093
P50
P1433
P1476
Induction of angiogenesis by normal and malignant plasma cells
@en
P2093
Anja Seckinger
Anna Jauch
Axel Benner
Bernard Klein
Jean-François Rossi
Jens Hillengass
Karène Mahtouk
Maud Condomines
Michael Hundemer
P304
P356
10.1182/BLOOD-2008-10-184226
P407
P577
2009-03-18T00:00:00Z